Europeiska unionen - svenska - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - gemenskapsförvärvade infektioner - antibakteriella medel för systemiskt bruk, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 och 5. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - svenska - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Finland - svenska - Ecolab

ecolab deutschland gmbh -

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

patheon softgels b.v. - naproxennatrium - kapsel, mjuk - 200 mg - propylenglykol hjälpämne; sorbitol hjälpämne; glycerol hjälpämne; naproxennatrium 220 mg aktiv substans - naproxen

Europeiska unionen - svenska - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydroklorid - kolorektala neoplasmer - antineoplastiska medel - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Europeiska unionen - svenska - EMA (European Medicines Agency)

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - hypofysiska och hypotalamiska hormoner och analoger - förebyggande av för tidig ägglossning hos patienter som genomgår en kontrollerad ovariestimulering, följt av oocytupptagning och assisterad reproduktiv teknik. i kliniska prövningar, cetrotide används med mänskliga menopausal gonadotropin (hmg), men begränsad erfarenhet med rekombinant follicule-stimulerande hormon (fsh) föreslog liknande effekt.

Europeiska unionen - svenska - EMA (European Medicines Agency)

eurocept international b. v. - para-aminosalicylsyra - tuberkulos - medel mot mykobakterier - granupas är indicerat för användning som en del av en lämplig kombinationsbehandling för multiresistent tuberkulos hos vuxna och pediatriska patienter från 28 dagars ålder och äldre när en effektiv behandlingsregim inte kan annars vara sammansatt av resistens eller tolerabilitet (se avsnitt 4. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Europeiska unionen - svenska - EMA (European Medicines Agency)

gilead sciences ireland uc - adefovirdipivoxil - hepatit b, kronisk - nukleosid- och nukleotid-omvänd transkriptashämmare - hepsera är indicerat för behandling av kronisk hepatit b hos vuxna med kompenserad leversjukdom med tecken på aktiv virusreplikation, kvarstående förhöjda serum-alanin-aminotransferas (alat) nivåer och histologiska bevis på aktiv leverinflammation och fibros. inledande av hepsera behandling bör ses endast när användningen av en alternativ antivirala medel med en högre genetisk barriär mot resistens är inte tillgängliga eller lämpliga (se avsnitt 5. 1);dekompenserad leversjukdom i kombination med andra agent utan kors-resistens mot hepsera.